RayKnowChina Research Map
Shortlist0

RecruitingBehçet diseasePhase 3

Registered title, quoted from ClinicalTrials.gov

A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

An open trial on Behçet disease, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 20 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 20

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Guilin Medical University桂林医学院附属医院GuilinHospital page
  2. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  3. Study siteBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page
  4. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  5. Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
  6. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  7. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  8. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  9. Study siteGuangdong Second Provincial General Hospital广东省第二人民医院GuangzhouHospital page
  10. Study siteLinyi People's Hospital临沂市人民医院LinyiHospital page
  11. Study sitePeking University First Hospital北京大学第一医院BeijingHospital page
  12. Study sitePeking University People's Hospital北京大学人民医院BeijingHospital page
  13. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  14. Study siteSecond Hospital of Hebei Medical University河北医科大学第二医院ShijiazhuangHospital page
  15. Study siteSecond Hospital of Shanxi Medical University山西医科大学第二医院TaiyuanHospital page
  16. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  17. Study siteThe University of Hong Kong–Shenzhen Hospital香港大学深圳医院ShenzhenHospital page
  18. Study siteThird Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院GuangzhouHospital page
  19. Study siteTongji Hospital同济大学附属同济医院ShanghaiHospital page
  20. Study siteXuanwu Hospital首都医科大学宣武医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06145893, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Currently having a malignant tumor, or a history of any malignant tumor within 5 years prior to screening (except for treatment-experienced squamous cell carcinoma in situ of the skin, basal cell carcinoma or cervical carcinoma in situ with no evidence of relapse within the past 12 months);

    Exclusion criterion 27

  3. Hemoglobin ≤85g/L;

    Exclusion criterion 15

    Platelets <100×10\^9/L;

    Exclusion criterion 17

    Serum creatinine >1.5 mg/dL (>132.6 μmol/L);

    Exclusion criterion 18

    Total bilirubin of >2.0 mg/dL (>34.2 μmol/L);

    Exclusion criterion 19

    Both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥1.5×ULN; Note: The above tests can be repeated at most once during the screening period. If the result within 2 weeks prior to randomization falls into the specified range, the subject is eligible for the study;

    Exclusion criterion 20

  4. Active lesions associated with BD in major organs requiring immunosuppressive treatment, e.g., those in lungs (e.g., pulmonary aneurysm), blood vessels (e.g., thrombophlebitis, recurrent malignant aneurysms), gastrointestinal tract (e.g., gastrointestinal ulcers), and central nervous system (e.g., meningoencephalitis); Note: Patients with refractory BD who experienced gastrointestinal perforation, active bleeding, or obstruction, etc. within 3 months prior to randomization are to be excluded.

    Exclusion criterion 1

    Positive for human immunodeficiency virus (HIV) antibody or treponema pallidum antibody test;

    Exclusion criterion 26

  5. Throughout the study period from signing of ICF through 3 months after the last study dose, women of childbearing potential and male subjects who have not undergone vasoligation should use effective contraceptive measures, including vasoligation, abstinence, intrauterine device (IUD), hormones (oral, patches, rings, injections, implants) and barrier methods (diaphragms, cervical caps, sponges, condoms);

    Inclusion criterion 8

    Female subjects who are pregnant or breast feeding;

    Exclusion criterion 33

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06145893, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Understanding and voluntarily signing the Informed Consent Form (ICF) for this study;
  • Age 18-75 years (inclusive), male or female;
  • Diagnosed as BD based on the ICBD-2013;
  • At least 2 oral ulcers present at V1 (screening), and:
  • at least 2 oral ulcers present at V2 (the day of randomization) when V2 occurs 14-56 days after V1; OR
  • at least 3 oral ulcers present at V2 (the day of randomization) when V2 occurs 0-13 days after V1;
  • Applicability of systemic treatment for oral ulcers: Based on the severity of the disease and the involved area, the investigator determines that the patient's oral ulceration is not suitable for topical treatment or that the patient's oral ulceration cannot be effectively controlled by topical treatment, so that systemic treatment is to be used;
  • Throughout the study period from signing of ICF through 3 months after the last study dose, women of childbearing potential and male subjects who have not undergone vasoligation should use effective contraceptive measures, including vasoligation, abstinence, intrauterine device (IUD), hormones (oral, patches, rings, injections, implants) and barrier methods (diaphragms, cervical caps, sponges, condoms);
  • Being able to comply with the follow-up schedule and other protocol requirements.

Exclusion Criteria:

  • Active lesions associated with BD in major organs requiring immunosuppressive treatment, e.g., those in lungs (e.g., pulmonary aneurysm), blood vessels (e.g., thrombophlebitis, recurrent malignant aneurysms), gastrointestinal tract (e.g., gastrointestinal ulcers), and central nervous system (e.g., meningoencephalitis); Note: Patients with refractory BD who experienced gastrointestinal perforation, active bleeding, or obstruction, etc. within 3 months prior to randomization are to be excluded.
  • Any clinically significant heart disease (including but not limited to: unstable ischemic heart disease, NYHA III/IV left ventricular failure, or myocardial infarction) or clinically significant 12-lead ECG abnormalities detected during the 6 months prior to screening, which, at the investigator's discretion, may put the subject at safety risk or may interfere with the study assessments;
  • Use of the following immunomodulatory therapies:
  • Colchicine within 7 days prior to randomization;
  • Perazathioprine, mycophenolate, baritinib, or tofacitinib within 10 days prior to randomization;
  • Cyclosporine, methotrexate, cyclophosphamide, thalidomide, or dapsone within 4 weeks (28 days) prior to randomization;
  • Biologics within 5 half-lives prior to randomization, e.g.:
  • Etanercept within 4 weeks prior to randomization;
  • Infliximab or leflunomide within 8 weeks prior to randomization;
  • Adalimumab, golimumab, abatacept, or tolizumab within 10 weeks prior to randomization;
  • Secukinumab within 6 months prior to randomization;
  • Intraarticular or systemic corticosteroid treatment prior to randomization and within 5 pharmacokinetic/pharmacodynamic half-lives; Note: For subjects with eye symptoms, glucocorticoid eye drops are allowed throughout the trial (except for within 24 hours prior to a trial visit).
  • Chinese patent medicines with immunomodulatory effect within 2 weeks prior to randomization; any Chinese pate nt medicines or decoctions within 2 weeks prior to randomization that might affect efficacy evaluation, or containing sinomenine, total glucoside of paeony, or tripterygium wilfordii, etc.;
  • Laboratory tests:
  • Hemoglobin ≤85g/L;
  • White blood cell count <3.0×10\^9/L or >14×10\^9/L;
  • Platelets <100×10\^9/L;
  • Serum creatinine >1.5 mg/dL (>132.6 μmol/L);
  • Total bilirubin of >2.0 mg/dL (>34.2 μmol/L);
  • Both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥1.5×ULN; Note: The above tests can be repeated at most once during the screening period. If the result within 2 weeks prior to randomization falls into the specified range, the subject is eligible for the study;
  • Use of potent inducers of cytochrome P450 enzymes (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin sodium) within 4 weeks prior to randomization;
  • Other autoimmune diseases or chronic inflammatory diseases associated with immunity, e.g., rheumatic fever, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, multiple sclerosis, Sjögren's syndrome, and inflammatory bowel disease;
  • Currently active infections or recurrent bacterial, fungal, viral, mycobacterial or other infectious diseases (including but not limited to tuberculosis, atypical mycobacteriosis, hepatitis B, hepatitis C, herpes zoster, histoplasmosis, and coccidiosis; however, onychomycosis is excluded), which, at the investigator's discretion, may put the subject at safety risk; Note: Subjects positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody, or with a history of active mycobacterial infection of any species (including Mycobacterium tuberculosis) within 3 years prior to screening visit should be excluded. Screening is permitted if the subject has been cured for at least 3 years prior to randomization with documentation available for verification;
  • Clinically significant chest X-ray or CT abnormalities, which, at the investigator's discretion, may put the subject at safety risk; Note: If a chest X-ray or CT was performed within 3 months prior to V1, the examination may be omitted for V1;
  • History of transplantation or immunodeficiency;
  • Positive for human immunodeficiency virus (HIV) antibody or treponema pallidum antibody test;
  • Currently having a malignant tumor, or a history of any malignant tumor within 5 years prior to screening (except for treatment-experienced squamous cell carcinoma in situ of the skin, basal cell carcinoma or cervical carcinoma in situ with no evidence of relapse within the past 12 months);
  • Use of any clinical investigational product within 4 weeks prior to randomization or 5 pharmacokinetic/pharmacodynamic half-lives, whichever is longer; Note: Subjects who have participated in HM005BD2S01 study are not eligible to participate in this trial;
  • Known allergy to the study drug or any of its components or allergic constitution;
  • A history of alcohol or drug abuse or dependence, or psychiatric disorder;
  • Any conditions that may interfere with oral drug absorption, e.g., subtotal gastrectomy, clinically significant diabetic gastrointestinal disease, or certain types of bariatric surgery such as gastric bypass surgery, not including procedures that simply separate the stomach into separate chambers such as gastric banding surgery;
  • Prior use of apremilast;
  • Female subjects who are pregnant or breast feeding;
  • Concomitant serious, progressive, or uncontrolled diseases, with which participation in the study may, at the investigator's discretion, put the subject at potential risk or affect the interpretation of study results.

Quoted from ClinicalTrials.gov, NCT06145893, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06145893, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06145893